Alexander Stojadinovic
Overview
Explore the profile of Alexander Stojadinovic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
220
Citations
4825
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tiwari A, Alcover K, Carpenter E, Thomas K, Krum J, Nissen A, et al.
Hum Vaccin Immunother
. 2024 Mar;
20(1):2323256.
PMID: 38544385
Cell-based therapeutic cancer vaccines use autologous patient-derived tumor cells, allogeneic cancer cell lines or autologous antigen presenting cells to mimic the natural immune process and stimulate an adaptive immune response...
2.
Cardellino A, Shah M, Hanlon J, Kelly K, Martin A, Roborel de Climens A, et al.
Front Psychol
. 2023 Sep;
14:1217793.
PMID: 37744571
Introduction: Advanced or metastatic non-small cell lung cancer (NSCLC) is associated with significant symptom burden. It is important to understand the impact of these disease-and treatment-related symptoms on patients' daily...
3.
Slowley A, Phiri K, Multani J, Casey V, Mpima S, Yasuda M, et al.
Thorac Cancer
. 2023 Aug;
14(28):2846-2858.
PMID: 37592826
Background: Real-world evidence is increasingly used to guide treatment and regulatory decisions for non-small cell lung cancer (NSCLC). Real-world treatment patterns and clinical outcomes among patients with advanced/metastatic NSCLC in...
4.
Zhu X, Durbin L, Kanas G, Phiri K, Keeven K, Clark O, et al.
Future Oncol
. 2023 Aug;
19(33):2237-2250.
PMID: 37529892
To estimate the incidence, prevalence and treated prevalence by line of therapy (LOT) for non-small-cell lung cancer (NSCLC) patients without driver mutations from 2021 to 2026. Country-specific registry data for...
5.
Sun X, Abrahamson P, Ballew N, Kalilani L, Phiri K, Bell K, et al.
Cancer Invest
. 2023 Jun;
41(6):571-592.
PMID: 37272675
This systematic review with embedded meta-analysis aimed to evaluate the clinical utility of circulating tumor DNA (ctDNA) in lung cancer. After screening and review of the Embase database search, 111...
6.
Man Y, Mannion C, Stojadinovic A, Peoples G, Cho W, Fu S, et al.
J Cancer
. 2023 Apr;
14(4):573-590.
PMID: 37057291
Breast cancer development and progression are believed to be a sequential process, from normal to hyperplastic, to , and to invasive and metastatic stages. Given that over 90% of cancer...
7.
Protic M, Krsmanovic O, Solajic N, Kukic B, Nikolic I, Bogdanovic B, et al.
J Cancer
. 2021 May;
12(12):3701-3714.
PMID: 33995645
More than 50% of patients with colorectal cancer (CRC) develop liver metastases during the natural course of disease. Surgical resection is currently the most potentially curative method in the treatment...
8.
Gao Y, Shang Q, Li W, Guo W, Stojadinovic A, Mannion C, et al.
J Cancer
. 2020 Aug;
11(17):5135-5149.
PMID: 32742461
Various antibiotics have been used in the treatment of cancers, via their anti-proliferative, pro-apoptotic and anti-epithelial-mesenchymal-transition (EMT) capabilities. However, increasingly studies have indicated that antibiotics may also induce cancer generation...
9.
Wallace T, Qian J, Avital I, Bay C, Man Y, Wellman L, et al.
J Cancer
. 2018 Jun;
9(12):2191-2202.
PMID: 29937939
: The androgen receptor (AR) regulates immune-related epithelial-to-mesenchymal transition (EMT), and prostate cancer (PCa) metastasis. Primary tumor-infiltrating lymphocytes (TILs) [CD3, CD4, and CD8 TILs] are potential prognostic indicators in PCa,...
10.
Flaherty D, Jalas J, Sim M, Stojadinovic A, Protic M, Lee D, et al.
Ann Surg Oncol
. 2018 Mar;
25(5):1374-1380.
PMID: 29532344
Background: The association between tumor mismatch repair status and obesity in colon cancer is not well understood. The authors of this study hypothesized that mismatch repair deficiency in colon cancer...